Nephrology

A peptide developed by scientists at Weill Cornell Medical College may expand the availability and durability of islet cell transplant for patients with type-1 diabetes.

A new tool is developed to identify patients who are most at risk for chronic kidney disease (CKD).

Discovery can lead to treatment strategies for diabetic patients to protect them from kidney failure and may provide a marker to determine which diabetic patients are at increased risk for future kidney disease.

Chronic kidney disease is a risk factor for peripheral artery disease (PAD)—a common but often undetected condition causing reduced blood flow in the legs.

More aggressive screening and treatment is needed in children with type 2 diabetes to prevent complications as they get older.

Treatment of new-onset type 1 diabetes with peptide is safe and associated with preserved beta-cell function.

Six per cent of patients with a BMI of more than 30 died in the first year after transplant, compared with three per cent of patients with a BMI of less than 30.

Since 85% of people with type 2 diabetes also may have elevated blood pressure, they should be given an ACE inhibitor to protect from kidney failure.

Study shows marked difference between Americans and leaner Norwegian patients.

New guidelines developed for the first time by the Kidney Disease Outcomes Quality Initiative provide detailed information on how to improve clinical outcomes in patients who have both diabetes and chronic kidney disease.